Avalyn Pharma (AVLN) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Avalyn Pharma (NASDAQ: AVLN):

• 5/27/2026 – Avalyn Pharma was upgraded by Zacks Research to “hold”.
• 5/26/2026 – Avalyn Pharma is now covered by Morgan Stanley. They set an “overweight” rating and a $53.00 price target on the stock.
• 5/26/2026 – Avalyn Pharma is now covered by Evercore Inc. They set an “outperform” rating and a $51.00 price target on the stock.
• 5/25/2026 – Avalyn Pharma is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $52.00 price target on the stock.
• 5/25/2026 – Avalyn Pharma is now covered by Guggenheim. They set a “buy” rating and a $80.00 price target on the stock.
• 5/25/2026 – Avalyn Pharma was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 5/25/2026 – Avalyn Pharma was upgraded by Guggenheim to “strong-buy”.
• 5/9/2026 – Avalyn Pharma was upgraded by Wall Street Zen to “hold”.

Insider Buying and Selling at Avalyn Pharma

In other Avalyn Pharma news, Director Jill Carroll bought 277,778 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the purchase, the director owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 34.06% increase in their position. The SEC filing for this purchase provides additional information.

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.